13F-NT: Royalty Pharma plc Files SEC Form 13F-NT
Form 13F-NT Filing
Royalty Pharma plc has filed a Form 13F-NT with the SEC for the quarter ended March 31, 2026, indicating no new holdings are reported in this filing.
Summary
- Royalty Pharma plc filed a Form 13F-NT for the quarter ending March 31, 2026.
- This filing is a notice report, meaning no new investment holdings are being reported by Royalty Pharma plc in this specific document.
- All holdings are understood to be reported by other reporting manager(s) associated with Royalty Pharma plc.
- The filing was signed by Jason Mehar, SVP, Investments & Deputy General Counsel, on May 14, 2026.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a neutral filing, as it is a procedural notice (13F-NT) and does not contain new financial performance data or strategic updates.
Future Outlook
No forward-looking statements or guidance are present in this filing.
Industry Context
StockSavvy.ai notes that Form 13F filings are standard disclosures for institutional investment managers, providing transparency on their equity holdings. The 13F-NT designation indicates a specific reporting strategy where holdings are consolidated under a primary manager or sub-manager.
Key Dates
| Date | Description |
|---|---|
| 03-31-2026 | Quarter Ended |
| 05-14-2026 | Date of Signing |
Keywords
SEC Filing, Form 13F-NT, Royalty Pharma plc, Investment Holdings, Financial Reporting, Securities, Institutional Investment Manager
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.